Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: A cost-effectiveness analysis

Journal of Managed Care Pharmacy

Volumn 20, Issue 7, 2014, Pages 722-732

  Vegter, Stefan ^a,b   Oosterhof, Piter ^c   van Boven, Job F M ^a   Stuurman Bieze, Ada G G ^d   Hiddink, Eric G ^a,d   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Health Economics Consultant Vegter Health Economic Research   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d Stichting Health Base   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEART INFARCTION; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NETHERLANDS; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRIMARY PREVENTION; REVASCULARIZATION; RHABDOMYOLYSIS; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; MEDICATION COMPLIANCE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PHARMACY; PROBABILITY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STATISTICAL MODEL; TIME; COHORT ANALYSIS; DRUG COST; FATALITY; HEALTH CARE COST; HEALTH INSURANCE; HEART MUSCLE REVASCULARIZATION; INCIDENCE; MORTALITY; PATIENT MONITORING; PRODUCTIVITY; REIMBURSEMENT; RISK REDUCTION;

AGED; CARDIOVASCULAR DISEASES; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MARKOV CHAINS; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; NETHERLANDS; PRIMARY PREVENTION; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; TIME FACTORS;

EID: 84901839517     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.7.722     Document Type: Article

References (61)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J. 2013;34(39):3017-27.
2. Stroes E. Statins and LDL-cholesterol lowering: an overview. Curr Med Res Opin. 2005;21(Suppl 6):S9-S16.
3. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2013;72(18):2365-73.
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
6. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59.
7. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-07.
9. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008;30(Pt 2):2228-40.
10. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90(9):1065-66.
11. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332(17):1125-31.
12. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62(2):338-51.
13. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
14. Shantsila A, Lip GY. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones. Int J Clin Pract. 2010;64(2):138-40.
15. Pharmapartners healthcare. Medicatie monitoring & optimalisatie- interventies van aantoonbare waarde. Available at: http://www.pharmapartners. nl/producten-en-diensten/toegevoegde-waarde-producten-en-diensten/medicatie-monitoring/. Accessed March 3, 2014.
16. Stuurman-Bieze AGG, Hiddink EG. Pharmaceutical care interventions, initiated by computerized drug prescription monitoring, improve drug compliance. PW Wetenschappelijk Platform. 2010;4(7):128-35.
17. van Boven JFM, Hiddink EG, Stuurman-Bieze AGG, Postma MJ, Vegter S. Structured medication surveillance for improving adherence to bisphosphonate therapy offers perspectives for cost-effective pharmaceutical care. PW Wetenschappelijk Platform. 2011;5(9):147-53.
18. Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions improve patients' adherence to lipid lowering medication. Ann Pharmacother. 2013;47(11):1448-56.
19. Boonen LHHM, van der Geest SA, Schut FT, Varkevisser M. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition. In: Dor A, ed. Pharmaceutical Markets and Insurance Worldwide. Bradford, UK: Emerald Group Publishing Ltd.; 2010:53-76.
20. Hakonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr Med Res Opin. 2009;25(10):2515-21.
21. Vegter S, van Boven JFM, Hiddink EG, Postma MJ. [Health economic evaluation of pharmaceutical patient care interventions]. In: Gier H, Bouvy M, De Smet P, eds. Handboek farmaceutische patiëntenzorg [Pharmaceutical Patient Care]. Houten, Netherlands: Prelum Uitgevers; 2013.
22. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of followup in the Renfrew and Paisley survey. Diabetes Care. 2005;28(7):1588-93.
23. Heintjes EM, Penning-van Beest FJ, Johansson S, Stalenhoef AF, Herings RM. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin. 2009;25(11):2621-29.
24. Koek HL, de Bruin A, Gast A, et al. Incidence of first acute myocardial infarction in the Netherlands. Neth J Med. 2007;65(11):434-41.
25. Koek HL, de Bruin A, Gast F, et al. Short- and long-term prognosis after acute myocardial infarction in men versus women. Am J Cardiol. 2006;98(8):993-99.
26. Bots ML, Jager-Geurts MH, Berger-van Sijl M, Reitsma JB, Dippel DWJ, de Bruin A. Kans op overlijden na een eerste ziekenhuisopname voor een cerebrovasculaire aandoening in Nederland. In: Jager-Geurts MH, Peters RJG, Dis van SJ, Bots ML, eds. Hart- en vaatziekten in Nederland 2006. Cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Den Haag: Nederlandse Hartstichting; 2006:57-76.
27. Vaartjes I, Reitsma JB, de Bruin A, et al. Nationwide incidence of first stroke and TIA in the Netherlands. Eur J Neurol. 2008;15(12):1315-23.
28. van Domburg RT, Takkenberg JJ, Meeter K, Valk SD, van Herwerden LA, Bogers AJ. [Coronary bypass surgery in 1971-80 and 1995-96: increased age and comorbidity, unchanged survival rates and fewer early reoperations 1 and 5 years postoperatively]. Ned Tijdschr Geneeskd. 2002;146(46):2192-96.
29. van Domburg RT, Vos J, Serruys PW. [Percutaneous transluminal coronary angioplasty in 1980-85 and 1995-96: more frequent multivessel disease, fewer reoperations and no change in mortality 1 and 5 years postoperatively]. Ned Tijdschr Geneeskd. 2002;146(46):2196-2200.
30. Cicala S, de Simone G, Gerdts E, et al. Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2010;28(6):1134-40.
31. Klungel OH, Heckbert SR, de Boer A, et al. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother. 2002;36(5):751-57.
32. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-90.
33. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-60C.
34. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS One. 2008;3(6):e2522.
35. Centraal Bureau voor de Statistiek, Statline. 2013. Available at: http://www.cbs.nl/. Accessed February 24, 2014.
36. GIPdatabank. Available at: www.gipdatabank.nl. Accessed February 24, 2014.
37. Heeg BM, Peters RJ, Botteman M, van Hout BA. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Pharmacoeconomics. 2007;25(9):769-82.
38. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.
39. Levin LA, Perk J, Hedback B. Cardiac rehabilitation-a cost analysis. J Intern Med. 1991;230(5):427-34.
40. Perk J. Returning to work after myocardial infarction. In: Perk J, Mathes P, Gohlke H, et al., eds. Cardiovascular Prevention and Rehabilitation. London: Springer-Verlag; 2007:317-23.
41. Hackett ML, Glozier N, Jan S, Lindley R. Returning to paid employment after stroke: the Psychosocial Outcomes In StrokE (POISE) cohort study. PLoS One. 2012;7(7):e41795.
42. Hlatky MA, Boothroyd D, Horine S, et al. Employment after coronary angioplasty or coronary bypass surgery in patients employed at the time of revascularization. Ann Intern Med. 1998;129(7):543-47.
43. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736-41.
44. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1-160, iii-iv.
45. Nationaal Kompas Volksgezondheid. Disease-specific disability weights for quality of life. 2011. Available at: http://www.nationaalkompas.nl/algemeen/meta-informatie/modellen/cdm/disease-specific-disability-weights-forquality- of-life/. Accessed February 28, 2014.
46. Stouthard MEA, Essink-Bot ML, Bonsel GJ, et al. Disability Weights for Diseases in the Netherlands. Rotterdam, The Netherlands: Department of Public Health, Erasmus University; 1997.
47. van Baal PH, Hoeymans N, Hoogenveen RT, de Wit GA, Westert GP. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr. 2006;4:1.
48. Dale W, Basu A, Elstein A, Meltzer D. Predicting utility ratings for joint health states from single healthstates in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making. 2008;28(1):102-12.
49. Fu AZ, Kattan MW. Utilities should not be multiplied: evidence from the preference-based scores in the United States. Med Care. 2008;46(9):984-90.
50. Carlsson CM, Papcke-Benson K, Carnes M, McBride PE, Stein JH. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging. 2002;19(10):793-805.
51. Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J. Long-term assessment of psychological well-being in a randomized placebocontrolled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med. 2000;160(20):3144-52.
52. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541-53.
53. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
54. Dieleman JP, van Wyk JT, van Wijk MA, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin. 2005;21(9):1461-68.
55. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther. 2008;30(1):195-205.
56. Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, Verschuren WM, Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol. Jul 2005;60(1):83-89.
57. Chapman RH, Ferrufino CP, Kowal SL, Classi P, Roberts CS. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract. 2010;64(2):169-81.
58. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124(2):146-53.
59. Mitchell AP, Simpson RJ. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012;5:373.
60. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144(5):326-36.
61. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243-54.